Safety of BromAc<sup>®</sup> with Mitomycin C during hyperthermic intraperitoneal chemotherapy (HIPEC): a preclinical study. [PDF]
Mekkawy AH +9 more
europepmc +1 more source
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20 years' experience. [PDF]
Farrell R, Liauw WS, Morris DL.
europepmc +1 more source
National Guidelines for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Malignancies: A Worldwide Systematic Review and Recommendations of Strength Analysis. [PDF]
Tonello M +5 more
europepmc +1 more source
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS): Age-Related Outcomes and a Look into the Future. [PDF]
Aguirre S +6 more
europepmc +1 more source
Cytoreductive Surgery (CS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Postoperative Evolution, Adverse Outcomes and Perioperative Risk Factors. [PDF]
Valencia-Sola L +5 more
europepmc +1 more source
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for children and young adults: experience from two high volume centers. [PDF]
Eckert M +9 more
europepmc +1 more source
Outcomes following diagnostic laparoscopy in patients with peritoneal carcinomatosis deemed ineligible for cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) due to disease burden. [PDF]
Smith PM +8 more
europepmc +1 more source
Single center experience with Hypotension Prediction Index (HPI) during cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC). [PDF]
L'Acqua C +3 more
europepmc +1 more source
CD8 + T-cells restrict the development of peritoneal metastasis and support the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC). [PDF]
Roth L +11 more
europepmc +1 more source

